Outcome | Continuous treatment | Sequential treatment | ||||||
---|---|---|---|---|---|---|---|---|

DAP (n = 853) | LZD (n = 853) | Risk ratio (95% CI) | P value | LZD (n = 217) | LZD-to-DAP (n = 217) | Risk ratio (95% CI) | P value | |

30-day all-cause mortality [n (%)] | 251 (29.4) | 298 (34.9) | 1.13 (1.02–1.26) | 0.015 | 75 (34.6) | 53 (24.4) | 1.29 (1.03–1.63) | 0.021 |

Infection-related mortality^{b} [n (%)] | 12 (1.4) | 46 (5.4) | 1.47 (1.19–2.09) | <0.001 | 16 (7.4) | 15 (6.9) | 1.04 (0.71–1.51) | 0.852 |

Hospital mortality [n (%)] | 250 (29.3) | 305 (35.8) | 1.16 (1.05–1.39) | 0.004 | 88 (40.6) | 71 (32.7) | 1.19 (0.97–1.46) | 0.090 |

Persistent VREF-BSI^{c}^{,}^{d} [n (%)] | 37 (6.4) | 54 (10.0) | 1.30 (1.02–1.67) | 0.027 | 19 (10.3) | 8 (5.4) | 1.54 (0.85–2.80) | 0.107 |

Duration of VREF-BSI (days)^{d}^{,}^{e} [median (IQR)] | 2 (1–3) | 3 (2–4) | <0.001 | 2 (1–5) | 2 (1–4) | 0.248 | ||

Hospital length of stay (days) [median (IQR)] | 21 (12–43) | 25 (14–47) | 0.001 | 24 (14–51) | 22 (10–45) | 0.165 |

↵a Categorical variables were compared by using a chi-square or Fisher's exact test. Continuous variables were compared by using the Mann-Whitney U test. Propensity scores were derived from the following covariates: age ≥ 65 years, concomitant pneumonia, facility complexity level, infectious diseases consultation, source of VREF-BSI, previous VRE colonization, concomitant β-lactam treatment, intensive care unit admission, malignancy, solid organ transplant, Charlson comorbidity index, moderate to severe renal disease, severe liver disease, neutropenia, or thrombocytopenia.

↵b Death during treatment with DAP or LZD without microbiological clearance from bloodstream.

↵c Lack of microbiological clearance after ≥7 days.

↵d Comparison among those with at least 1 follow-up blood culture while on treatment (LZD [

*n*= 539], DAP [*n*= 578]).↵e Comparison among those with at least 1 follow-up blood culture while on treatment (LZD [

*n*= 184], LZD-to-DAP [*n*= 147]).